Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + Bispecific Antibody in RRMM
NCT06822972Phase 2Recruiting
- Sponsor
- Duke University
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in multiple myeloma (MM), sponsored by Duke University. Started Aug 2025; status: recruiting.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06822972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06822972.